ReviewJournal of clinical medicine2024
Remimazolam and Its Place in the Current Landscape of Procedural Sedation and General Anesthesia.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- RemimazolamPeerJ · 2026Pooled it
- Remimazolam vs propofol for postoperative delirium in adults undergoing general anesthesia: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Remimazolam in pediatric anesthesia: a systematic review for clinical decision-making.Frontiers in pediatrics · 2025Pooled it
- Remimazolam tosilate combined with remifentanil hydrochloride alleviates dental phobia in patients undergoing tooth extraction surgeries.Odontology · 2026Trial
- The Effects of Remimazolam Tosylate on Postoperative Memory Function in Young and Middle-Aged Patients Undergoing Laparoscopic Surgery.Drug design, development and therapy · 2026Trial
- Effects of remimazolam on postanesthetic shivering and related clinical responses in patients undergoing cesarean section.Frontiers in medicine · 2026Trial
- Comparison of Remimazolam and Dexmedetomidine on Postoperative Delirium and Emergence Agitation in Elderly Patients Undergoing Thoracoscopic Surgery: A Randomized, Double-Blind, Non-Inferiority Trial.Drug design, development and therapy · 2025Trial
- Low-Dose Alfentanil Effectively Reduces the ED50 of Remimazolam for Loss of Consciousness in Pediatric Patients Undergoing General Anesthesia: A Study Using Up-and-Down Sequential Allocation Method.Drug design, development and therapy · 2025Trial
- Association between continuous phenylephrine infusion and hemodynamic stability in patients undergoing gastrointestinal endoscopy under remimazolam sedation: a retrospective cohort study.BMC anesthesiology · 2026Article
- Application value and safety advantages of remimazolam tosilate in sedation for emergency rescue endotracheal intubation.American journal of translational research · 2026Article
- Remimazolam in anesthesia and sedation: A narrative review.Journal of anesthesia and translational medicine · 2025Review
- Safety and efficacy of remimazolam in sedation dentistry: a scoping review.Journal of dental anesthesia and pain medicine · 2025Review
- Remimazolam in pediatric ambulatory anesthesia: a critical review and clinical perspective.Frontiers in medicine · 2025Review
- Effect of remimazolam toluene sulfonate on the cognitive function of juveniles and its mechanism of action.European journal of medical research · 2024Article
- Anesthesia for Bronchoscopy-An Update.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remimazolam was derived from its parent compound by adding an ester linkage into its structure so that the drug becomes a substrate for ester metabolism. As a result, it undergoes organ-independent ester hydrolysis, although the clinical benefits in terms of shorter recovery are not uniformly observed in clinical practice. Remimazolam is mainly tested in procedural sedation. In comparison to propofol, the current gold standard for procedural sedation, its proposed attractiveness is shorter wake-up times and a clear-headed recovery. Its clear advantages over propofol are better hemodynamic stability, lack of pain on injection and availability of a reversal agent in the form of flumazenil. Data on patient and proceduralist satisfaction are lacking. Remimazolam is also used for induction and maintenance of general anesthesia in Japan (where it is approved for this purpose). In this scenario, it is not clear if it can achieve the same degree of lack of recall as propofol. The use of remimazolam in obstetrics, pediatrics and high-risk populations is an emerging area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.